Abstract
The incidence of severe adverse events (SAEs) and associated risk factors in hematopoietic cell transplantation donors needs to be clarified for related donors (relatives of the transplant recipient), whose criteria for donation are more lenient than for unrelated donors. Data from related donors registered in the Japanese national data registry database between 2005 and 2021 were evaluated to determine the association of short-term SAE incidence with donor characteristics at registration.
Fourteen of 4339 bone marrow (BM) donors (0.32%) and 54 of 10,684 peripheral blood stem cell (PBSC) donors (0.51%) experienced confirmed SAEs during the short donation period. No deaths were observed. Past medical history was a common risk factor for SAEs in both BM and PBSC donors. Age of 60 years or older and female sex were identified as risk factors for SAEs in PBSC donors. Female sex was also a risk factor for poor mobilization, which resulted in discontinuation of PBSC collection.
Although donors should be selected carefully, a certain level of safety is ensured for related donors in Japan. Donor safety should be further increased by improving the selection method for related donors and extending the follow-up period.
Similar content being viewed by others
References
Anderlini P, Korbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D, et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood. 1997;90:903–8.
Halter J, Kodera Y, Ispizua AU, Greinix HT, Schmitz N, Favre G, et al. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica. 2009;94:94–101.
Horowitz MM, Confer DL. Evaluation of hematopoietic stem cell donors. Hematol Am Soc Hematol Educ Progr. 2005;2005:469–75.
Halter JP, van Walraven SM, Worel N, Bengtsson M, Hagglund H, Nicoloso de Faveri G, et al. Allogeneic hematopoietic stem cell donation-standardized assessment of donor outcome data: a consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT). Bone Marrow Transpl. 2013;48:220–5.
Shaw BE, Ball L, Beksac M, Bengtsson M, Confer D, Diler S, et al. Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations. Bone Marrow Transpl. 2010;45:832–8.
Holig K, Kramer M, Kroschinsky F, Bornhauser M, Mengling T, Schmidt AH, et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood. 2009;114:3757–63.
Anthias C, Shaw BE, Kiefer DM, Liesveld JL, Yared J, Kamble RT, et al. Significant improvements in the practice patterns of adult related donor care in US transplantation centers. Biol Blood Marrow Transpl. 2016;22:520–7.
Clare S, Mank A, Stone R, Davies M, Potting C, Apperley JF, et al. Management of related donor care: a European survey. Bone Marrow Transpl. 2010;45:97–101.
O’Donnell PV, Pedersen TL, Confer DL, Rizzo JD, Pulsipher MA, Stroncek D, et al. Practice patterns for evaluation, consent, and care of related donors and recipients at hematopoietic cell transplantation centers in the United States. Blood. 2010;115:5097–101.
Kodera Y, Yamamoto K, Harada M, Morishima Y, Dohy H, Asano S, et al. PBSC collection from family donors in Japan: a prospective survey. Bone Marrow Transpl. 2014;49:195–200.
Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transpl. 2013;48:452–8.
Ruesch M, Amar El Dusouqui S, Buhrfeind E, Buser A, Chalandon Y, Frey BM, et al. Basic characteristics and safety of donation in related and unrelated haematopoietic progenitor cell donors - first 10 years of prospective donor follow-up of Swiss donors. Bone Marrow Transpl. 2022;57:918–24.
Anthias C, Ethell ME, Potter MN, Madrigal A, Shaw BE. The impact of improved JACIE standards on the care of related BM and PBSC donors. Bone Marrow Transpl. 2015;50:244–7.
Switzer GE, Bruce J, Kiefer DM, Kobusingye H, Drexler R, Besser RM, et al. Health-related quality of life among older related hematopoietic stem cell donors (>60 Years) is equivalent to that of younger related donors (18 to 60 Years): a related donor safety study. Biol Blood Marrow Transpl. 2017;23:165–71.
Pulsipher MA, Logan BR, Chitphakdithai P, Kiefer DM, Riches ML, Rizzo JD, et al. Effect of aging and predonation comorbidities on the related peripheral blood stem cell donor experience: report from the related donor safety study. Biol Blood Marrow Transpl. 2019;25:699–711.
Lysak D, Koristek Z, Gasova Z, Skoumalova I, Jindra P. Efficacy and safety of peripheral blood stem cell collection in elderly donors; does age interfere? J Clin Apher. 2011;26:9–16.
Murata M, Harada M, Kato S, Takahashi S, Ogawa H, Okamoto S, et al. Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors. Bone Marrow Transpl. 1999;24:1065–71.
Ings SJ, Balsa C, Leverett D, Mackinnon S, Linch DC, Watts MJ. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol. 2006;134:517–25.
Bailen R, Perez-Corral AM, Pascual C, Kwon M, Serrano D, Gayoso J, et al. Factors predicting peripheral blood progenitor cell mobilization in healthy donors in the era of related alternative donors: Experience from a single center. J Clin Apher. 2019;34:373–80.
Suzuya H, Watanabe T, Nakagawa R, Watanabe H, Okamoto Y, Onishi T, et al. Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors. Vox Sang. 2005;89:229–35.
Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, et al. Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. Haematologica. 2019;104:844–54.
Farhadfar N, Ahn KW, Bo-Subait S, Logan B, Stefanski HE, Hsu JW, et al. The impact of pre-apheresis health related quality of life on peripheral blood progenitor cell yield and donor’s health and outcome: secondary analysis of patient-reported outcome data from the rdsafe and bmt ctn 0201 clinical trials. Transpl Cell Ther. 2022;28(603):e1–7.
Acknowledgements
The authors are grateful for the work of all the physicians and data managers who contributed valuable related donor data to the Related Hematopoietic Stem Cell Donor Registry Center.
Funding
None to disclose.
Author information
Authors and Affiliations
Contributions
RY designed the study, analyzed data, and wrote the manuscript. TH, HY, and NT designed the study, advised on methods, and wrote the manuscript. ND, KI, KM, TF, HN, SO, NH, JI, TA, MT, YK, TK, YM, and YK collected data and revised the manuscript. MH, and HY collected data, revised the manuscript, and were responsible for data management at JDCHCT. YA managed the unified registry database and revised the manuscript. All authors approved the final version of the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
M.H. received research grants and lecture fees from Kyowa Kirin Co. Ltd. and Chugai Pharma Co. Ltd. The other authors declare that they have no conflicts of interest to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
About this article
Cite this article
Yanagisawa, R., Hirakawa, T., Doki, N. et al. Severe short-term adverse events in related bone marrow or peripheral blood stem cell donors. Int J Hematol 117, 421–427 (2023). https://doi.org/10.1007/s12185-022-03489-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-022-03489-4